← All trials
NCT05260437
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 24, 2022
- Primary completion
- Apr 3, 2023
- Completion date
- Apr 3, 2023
- First posted
- Mar 2, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 180
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
- CureVac AGCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.